Neuphoria Therapeutics Inc. (NEUP)
| Market Cap | 11.07B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.82M |
| Shares Out | 3.51B |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,978 |
| Open | 3.180 |
| Previous Close | 3.010 |
| Day's Range | 3.091 - 3.249 |
| 52-Week Range | 2.124 - 16.080 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 13, 2025 |
About NEUP
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer... [Read more]
Financial Performance
Financial StatementsNews
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangemen...